Article Versions Notes

Miyawaki T, Kenmotsu H, Ko R, Oshima M, Shukuya T, Shikama N, Takahashi K. Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease, and Oligo-Progressive Disease in EGFR-Mutated Non-Small-Cell Lung Cancer. Cancers. 2025; 17(13):2202. https://doi.org/10.3390/cancers17132202

Miyawaki, Taichi, Hirotsugu Kenmotsu, Ryo Ko, Masaki Oshima, Takehito Shukuya, Naoto Shikama, and Kazuhisa Takahashi. 2025. "Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease, and Oligo-Progressive Disease in EGFR-Mutated Non-Small-Cell Lung Cancer" Cancers 17, no. 13: 2202. https://doi.org/10.3390/cancers17132202

Miyawaki, T., Kenmotsu, H., Ko, R., Oshima, M., Shukuya, T., Shikama, N., & Takahashi, K. (2025). Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease, and Oligo-Progressive Disease in EGFR-Mutated Non-Small-Cell Lung Cancer. Cancers, 17(13), 2202. https://doi.org/10.3390/cancers17132202